Ian Beaumont, Bowel Cancer UK
Media playback is unsupported on your device

NICE decision used 'flawed' studies say cancer charity

The health watchdog NICE is being criticised for a provisional decision not to recommend the cancer drug avastin to treat bowel cancer on the NHS.

It says the cost of avastin, at about £21,000 per patient, does not justify its benefits.

Cancer charities are hoping the new cancer drug fund set up by the government will give greater access to the treatment.

Ian Beaumont from the charity Bowel Cancer UK told BBC Breakfast that the studies used by NICE to make their decision were "flawed".

  • 24 Aug 2010